ENTA
USDEnanta Pharmaceuticals Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$7.565
Máximo
$8.470
Mínimo
$7.475
Volumen
0.24M
Fundamentos de la Empresa
Capitalización de Mercado
169.9M
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
0.20M
Bolsa
NMS
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
MAVYRET® (glecaprevir/pibrentasvir) is Now the Only Direct Acting Antiviral Therapy Approved to Treat Patients with Acute Hepatitis C Virus (HCV) in Eight Weeks with a 96% Cure Rate1*† FDA Approval Now
JMP Securities Maintains Market Outperform on Enanta Pharma, Raises Price Target to $24
JMP Securities analyst Roy Buchanan maintains Enanta Pharma with a Market Outperform and raises the price target from $23 to $24.
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D.,
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's
Acciones Relacionadas
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.